1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2,3-Dioxygenase (IDO)

Indoleamine 2, 3-dioxygenase (IDO) is an intracellular enzyme that catalyzes the transformation of L-tryptophan to N-formylkynurenine, which is the first and rate-controlling step in the kynurenine pathway.

IDO is a rate-limiting enzyme that catalyzes the degradation of tryptophan into kynurenine and is recognized to exert a tolerizing effect on T cells that require tryptophan to proliferate5. IDO also plays an important role in the activation and regulation of functionally quiescent regulatory T cells.

IDO is a heme-containing enzyme that catalyzes the oxidative cleavage of 2,3 double bond of indole ring. IDO has the ability to inhibit T-cell activation by tryptophan starvation, whereas T-cell survival and proliferation are regulated by O2 free radicals and kynurenine derivatives. IDO plays a crucial role in autoimmunity,infections and malignancies.

Indoleamine-2,3-dioxygenase (IDO) one of the most important immunoregulator enzyme responsible for metabolism of tryptophan as part of Kynurenin pathway. Tryptophan is catabolized in the tumor tissue by the rate-limiting enzyme IDO expressed in tumor cells or antigen presenting cells.

Indoleamine 2,3-Dioxygenase (IDO) Isoform Specific Products:

  • IDO1

  • IDO2

  • IDO

Indoleamine 2,3-Dioxygenase (IDO) 相关产品 (27):

Cat. No. Product Name Effect Purity
  • HY-15760
    Necrostatin-1 Inhibitor 99.20%
    Necrostatin-1 (Nec-1) 是一种有效,选择性和可渗透细胞的坏死性凋亡 (necroptosis) 抑制剂,在Jurkat细胞中的 EC50 为490 nM。Necrostatin-1 (Nec-1) 通过抑制坏死性凋亡途径中 (RIP1) 激酶域起作用。
  • HY-15689
    Epacadostat Inhibitor 99.65%
    Epacadostat (INCB 024360) 是一种有效,选择性的 IDO1 抑制剂, IC50 为 71.8 nM±17.5 nM。
  • HY-101560
    Linrodostat Inhibitor 99.92%
    Linrodostat (BMS-986205; ONO-7701) 是一个有选择性的吲哚胺 2,3-双加氧酶 1 (IDO1) 抑制剂。
  • HY-16724
    Indoximod Inhibitor 98.98%
    Indoximod (D-1MT, NLG8189)是吲哚胺2,3-双加氧酶 (IDO) 通路抑制剂,Ki 为19 μM。
  • HY-13983
    IDO-IN-7 Inhibitor 99.92%
    IDO-IN-7 (NLG-919 analogue) 是一种有效的 IDO1 抑制剂, IC50为 38 nM。
  • HY-111540
    LY-3381916 Inhibitor
    LY-3381916 是一种有效、选择性、可透过血脑屏障的 IDO1 抑制剂,能够与缺乏血红素的 apo-IDO1 结合,但无法与结合有成熟血红素的 IDO1 结合。
  • HY-128355
    IDO/TDO-IN-1 Inhibitor
    IDO/TDO-IN-1 (compound 25) 是一种高效的、具有口服活性的吲哚胺-2,3-双加氧酶 (IDO) 和色氨酸 2,3-双加氧酶 (TDO) 双重抑制剂,IC50 值分别为 9.7 nM 和 47 nM。
  • HY-112147
    IDO1 and HDAC1 Inhibitor Inhibitor
    IDO1 and HDAC1 Inhibitor (Compound 10) 是双重 IDO1HDAC1 抑制剂,IC50 分别为 69.0 nM 和 66.5 nM。
  • HY-18770B
    Navoximod Inhibitor 99.99%
    Navoximod (GDC-0919; NLG-​919) 是一种有效的 IDO (indoleamine-(2,3)-dioxygenase) 抑制剂,Ki/EC50 分别为 7 nM/75 nM。
  • HY-N0736
    Coptisine chloride Inhibitor 99.29%
    Coptisine chloride 是从黄连中分离到的生物碱,是一种有效的非竞争性的 IDO 抑制剂,Ki 值为 5.8 μM,IC50 值为 6.3 μM。
  • HY-101111
    PF-06840003 Inhibitor 99.80%
  • HY-18769
    IDO-IN-4 Inhibitor 99.40%
    IDO-IN-4 是一种有效的吲哚胺-2,3-双加氧酶1 (IDO-1) 抑制剂,详细信息请参考专利文献 WO2014150677A1 中的化合物 example 1 enantiomer 1。
  • HY-112164
    IACS-8968 Inhibitor 98.13%
    IACS-8968 是 IDOTDO 的双抑制剂,其 pIC50s 值分别为 6.43,<5。
  • HY-100687
    GNF-PF-3777 Inhibitor
    GNF-PF-3777 (8-Nitrotryptanthrin) 是一种有效的人吲哚胺2,3-双加氧酶 2 (hIDO2) 抑制剂,有效降低 IDO2 活性,Ki 值为 0.97 μM。
  • HY-15683
    IDO5L Inhibitor 99.89%
    IDO5L 是一种有效的吲哚胺-2,3-双加氧酶 (IDO) 抑制剂,IC50 为 67 nM。
  • HY-100771
    IDO-IN-2 Inhibitor 98.54%
    IDO-IN-2是IDO的抑制剂,来自专利WO / 2015031295A1化合物实例1。其在HeLa和HEK293细胞中的IC50值分别为0.068和 0.16μM。
  • HY-18770
    IDO-IN-5 Inhibitor 99.90%
    IDO-IN-5 (NLG-1489) 是一种哚胺-2,3-双加氧酶 (IDO) 抑制剂,IC50 值为 1-10 μM,详细信息请参考专利文献 WO2012142237A1 中的化合物 1489。
  • HY-18770C
    IDO-IN-8 Inhibitor 99.99%
    IDO-IN-8 (NLG-1487) 是一种哚胺-2,3-双加氧酶 (IDO) 抑制剂,IC50 值为 1-10 μM,详细信息请参考专利文献 WO2012142237A1 中的化合物 1487。
  • HY-16987
    IDO-IN-3 Inhibitor 99.88%
    IDO-IN-3 是一种有效的吲哚胺-2,3-双加氧酶 (IDO) 抑制剂,IC50 为 290 nM。
  • HY-115122
    IDO-IN-12 Inhibitor 99.22%
    IDO-IN-12 是一个吲哚胺 2,3-双加氧酶 (IDO) 抑制剂,来自专利 WO 2017181849 A1。
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.